These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 3547618)

  • 61. In vitro activities of the spectinomycin analog U-63366 and four quinolone derivatives against Neisseria gonorrhoeae.
    Peeters M; Van Dyck E; Piot P
    Antimicrob Agents Chemother; 1984 Oct; 26(4):608-9. PubMed ID: 6240224
    [TBL] [Abstract][Full Text] [Related]  

  • 62. In-vitro selection of bacteria resistant to the 4-quinolone agents.
    Limb DI; Dabbs DJ; Spencer RC
    J Antimicrob Chemother; 1987 Jan; 19(1):65-71. PubMed ID: 3470281
    [TBL] [Abstract][Full Text] [Related]  

  • 63. In vitro activity of CI-934 compared with ciprofloxacin, enoxacin, norfloxacin, and vancomycin.
    Floyd-Reising SA; Kelley SG; Hindler JA; Young LS
    Diagn Microbiol Infect Dis; 1987 Apr; 6(4):301-6. PubMed ID: 3472704
    [TBL] [Abstract][Full Text] [Related]  

  • 64. In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections.
    Naber KG; Sörgel F; Gutzler F; Bartosik-Wich B
    Infection; 1985; 13(5):219-24. PubMed ID: 2933340
    [TBL] [Abstract][Full Text] [Related]  

  • 65. In-vitro activity of ofloxacin, a quinolone carboxylic acid compared to other quinolones and other antimicrobial agents.
    Kumada T; Neu HC
    J Antimicrob Chemother; 1985 Nov; 16(5):563-74. PubMed ID: 3865923
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Activity of nadifloxacin against methicillin-resistant Staphylococcus aureus isolated from skin infections: comparative study with seven other fluoroquinolones.
    Nishijima S; Nakagawa M; Tsuboi N; Akamatsu H; Horio T; Fujita M; Kawabata S
    J Int Med Res; 1996; 24(1):12-6. PubMed ID: 8674789
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [In vitro antibacterial activity of new derivatives of pyridonecarboxylic acid, norfloxacin, ofloxacin, enoxacin and ciprofloxacin, against Vibrio cholerae O-1].
    Matsushita S; Yamada S; Kudoh Y; Ohashi M
    Kansenshogaku Zasshi; 1987 Mar; 61(3):292-6. PubMed ID: 3112282
    [No Abstract]   [Full Text] [Related]  

  • 68. Comparative in-vitro activity of five fluoroquinolones against mycobacteria.
    Davies S; Sparham PD; Spencer RC
    J Antimicrob Chemother; 1987 May; 19(5):605-9. PubMed ID: 3112094
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Membrane permeability of Pseudomonas aeruginosa to 4-quinolones.
    Kubesch P; Wehsling M; Tümmler B
    Zentralbl Bakteriol Mikrobiol Hyg A; 1987 Jun; 265(1-2):197-202. PubMed ID: 3118593
    [TBL] [Abstract][Full Text] [Related]  

  • 70. In vivo sequential selection of Escherichia coli with topoisomerase- and efflux-mediated misleading quinolone resistance phenotypes.
    Smati M; Emond JP; Arlet G; Tankovic J
    Microb Drug Resist; 2012 Feb; 18(1):19-22. PubMed ID: 22043806
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Quinolones in vitro.
    Willems FT
    Pharm Weekbl Sci; 1986 Feb; 8(1):26-8. PubMed ID: 3960690
    [TBL] [Abstract][Full Text] [Related]  

  • 72. 4-quinolones inhibit biotransformation of caffeine.
    Harder S; Staib AH; Beer C; Papenburg A; Stille W; Shah PM
    Eur J Clin Pharmacol; 1988; 35(6):651-6. PubMed ID: 2853056
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Inhibition of conjugal transfer by new quinolinic compounds.
    Oliva B; Selan L; Ravagnan G; Renzini G
    Chemioterapia; 1985 Jun; 4(3):199-201. PubMed ID: 3161641
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The in-vitro activity of CI-934 compared with that of other new 4-quinolones and nalidixic acid.
    King A; Shannon K; Slegg J; Phillips I
    J Antimicrob Chemother; 1986 Aug; 18(2):163-9. PubMed ID: 3463557
    [TBL] [Abstract][Full Text] [Related]  

  • 75. In vitro activities of five new quinolones against 88 genital and neonatal Haemophilus isolates.
    Quentin R; Koubaa N; Cattier B; Gavignet M; Goudeau A
    Antimicrob Agents Chemother; 1988 Jan; 32(1):147-9. PubMed ID: 3258143
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Review of the 4-quinolones.
    Eggleston M; Park SY
    Infect Control; 1987 Mar; 8(3):119-25. PubMed ID: 3553053
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Development of resistance to nalidixic acid and the fluoroquinolones after the introduction of norfloxacin and ofloxacin.
    Kresken M; Wiedemann B
    Antimicrob Agents Chemother; 1988 Aug; 32(8):1285-8. PubMed ID: 3142353
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Activity of flumequine against Escherichia coli: in vitro comparison with nalidixic and oxolinic acids.
    Greenwood D
    Antimicrob Agents Chemother; 1978 Mar; 13(3):479-83. PubMed ID: 400825
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [In vitro antimicrobial activities of new quinolone antibiotics against Mycoplasma pneumoniae].
    Gohara Y; Arai S; Kuwano K; Kawashima T; Matsu-Ura I
    Nihon Saikingaku Zasshi; 1992 Mar; 47(2):387-93. PubMed ID: 1318981
    [TBL] [Abstract][Full Text] [Related]  

  • 80. In vitro and in vivo activity of NY-198, a new difluorinated quinolone.
    Hirose T; Okezaki E; Kato H; Ito Y; Inoue M; Mitsuhashi S
    Antimicrob Agents Chemother; 1987 Jun; 31(6):854-9. PubMed ID: 3476021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.